Viral Disease Animal Models

Viral disease animal models use animals as experimental subjects to simulate human viral infections. 

These models are essential for studying disease mechanisms, vaccine development, and antiviral drug efficacy. 

Among various options, mice are widely used in virology research due to their stable genetic background, short reproductive cycle, low maintenance cost, and well-established genetic manipulation techniques. 

Applications of Viral Disease Animal Models

• Vaccine and Drug Testing: Evaluating the immune response of vaccines and the efficacy and safety of antiviral drugs, such as early-stage trials for COVID-19 vaccines.
• Disease Mechanism Research: Investigating how viruses induce pathological changes, such as the dengue virus causing vascular leakage.
• Host-Pathogen Interactions: Analyzing immune responses, such as the impact of cytokine storms on severe viral infections.

SIDSCO Biomedical Co., Ltd., a subsidiary of Leadgene Biomedical, is a TAF-certified and GLP-compliant laboratory authorized to conduct toxicity testing for pharmaceuticals, health foods, and regenerative medicine products. 

SIDSCO has developed various viral disease models, including dengue virus, Zika virus, Japanese encephalitis virus, and enterovirus A71. 

In addition to disease animal models, SIDSCO operates an in-house pathology laboratory with contracted veterinary pathologists, offering a wide range of histological staining and disease interpretation services for post-experiment analysis.

Furthermore, SIDSCO provides comprehensive testing services, including the collection of various animal tissues and analysis of cytokines, biomarkers, nucleic acids, proteins, and histopathology, delivering in-depth insights into drug bioactivity.

This platform enables efficient antiviral drug screening and fundamental virology research. 

SIDSCO's dengue virus infection model utilizes ICR neonatal mice infected with Dengue Virus Serotype 2. Approximately 6–8 days after virus injection, untreated mice exhibit lethal symptoms. (Reference: Tseng et al., 2016)

Model Advantages

• Short experimental cycle, allowing for rapid assessment of drug-virus interactions in vivo.
• No licensing required, making it a cost-effective service.
• High throughput, enabling simultaneous testing of multiple samples.

Available Data Outputs

• Animal survival rate
• Clinical symptom scoring
• Body weight changes
• Viral load in different organs
• Histological analysis
• Quantification of target proteins or specific RNA

This platform enables efficient antiviral drug screening and fundamental virology research.

SIDSCO's Zika virus infection model utilizes ICR neonatal mice infected with the Zika virus. Approximately 6 days after virus injection, untreated mice exhibit lethal symptoms. (Reference: Wu et al., 2018)

Model Advantages

• Short experimental cycle, allowing for rapid assessment of drug-virus interactions in vivo.
• No licensing required, making it a cost-effective service.
• High throughput, enabling simultaneous testing of multiple samples.

Available Data Outputs

• Animal survival rate
• Clinical symptom scoring
• Body weight changes
• Viral load in different organs
• Histological analysis
• Quantification of target proteins or specific RNA